Allosteric modulator potentiates β2AR agonist–promoted bronchoprotection in asthma models
Journal of Clinical Investigation · 15.09.2023 · 133 (18)
DOI: 10.1172/jci167337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.09.2023. Verfasst von Seungkirl Ahn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Asthma. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
Asthma is a chronic inflammatory disease associated with episodic airway narrowing. Inhaled β2-adrenergic receptor (β2AR) agonists (β2-agonists) promote - with limited efficacy - bronchodilation in asthma. All β2-agonists are canonical orthosteric ligands that bind the same site as endogenous epinephrine. We recently isolated a β2AR-selective positive allosteric modulator (PAM), compound-6 (Cmpd-6), which binds outside of the orthosteric site and modulates orthosteric ligand functions. With the emerging therapeutic potential of G-protein coupled receptor allosteric ligands, we investigated the impact of Cmpd-6 on β2AR-mediated bronchoprotection. Consistent with our findings using human β2ARs, Cmpd-6 allosterically potentiated β2-agonist binding to guinea pig β2ARs and downstream signaling of β2ARs. In contrast, Cmpd-6 had no such effect on murine β2ARs, which lack a crucial amino acid in the Cmpd-6 allosteric binding site. Importantly, Cmpd-6 enhanced β2 agonist-mediated bronchoprotection against methacholine-induced bronchoconstriction in guinea pig lung slices, but - in line with the binding studies - not in mice. Moreover, Cmpd-6 robustly potentiated β2 agonist-mediated bronchoprotection against allergen-induced airway constriction in lung slices obtained from a guinea pig model of allergic asthma. Cmpd-6 similarly enhanced β2 agonist-mediated bronchoprotection against methacholine-induced bronchoconstriction in human lung slices. Our results highlight the potential of β2AR-selective PAMs in the treatment of airway narrowing in asthma and other obstructive respiratory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, Florida, USA.
- School of Nursing, Duke University, Durham, North Carolina, USA.
- Department of Biochemistry and.
- Howard Hughes Medical Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- Howard Hughes Medical Institute
- NIH
- Integra Connect Grant
Zitieren
APA
Ahn, S., Maarsingh, H., Walker, J. K., Liu, S., Hegde, A., Sumajit, H. C., Kahsai, A. W., & Lefkowitz, R. J. (2023). Allosteric modulator potentiates β2AR agonist–promoted bronchoprotection in asthma models. Journal of Clinical Investigation, 133(18). https://doi.org/10.1172/jci167337
Vancouver
Ahn S, Maarsingh H, Walker JK, Liu S, Hegde A, Sumajit HC, et al. Allosteric modulator potentiates β2AR agonist–promoted bronchoprotection in asthma models. Journal of Clinical Investigation. 2023;133(18). doi:10.1172/jci167337
BibTeX
@article{Ahn2023,
author = {Ahn, Seungkirl and Maarsingh, Harm and Walker, Julia Kl and Liu, Samuel and Hegde, Akhil and Sumajit, Hyeje C and Kahsai, Alem W and Lefkowitz, Robert J},
title = {Allosteric modulator potentiates β2AR agonist–promoted bronchoprotection in asthma models},
journal = {Journal of Clinical Investigation},
year = {2023},
volume = {133},
number = {18},
doi = {10.1172/jci167337}
}
EUVIMED